Company intelligence / Profile preview

BioGeneration Ventures

Naarden, North Holland, Netherlandsbiogenerationventures.com ↗

Ownership: Private
Development stage: Other

Overview

BioGeneration Ventures (BGV) does not develop drugs directly but has enabled the creation and growth of numerous biotech companies that have advanced programs into late-stage clinical trials and achieved major exits. Portfolio highlights include Acerta Pharma’s sale to AstraZeneca for up to $7 billion and Dezima Pharma’s sale to Amgen for up to $1.55 billion[7][8]. Recent portfolio company Azafaros, founded by BGV, has advanced two Phase 3 programs in rare lysosomal storage disorders as of May 2025[5].

Industry: Investors

Drug pipeline

1 asset

acalabrutinib

Commercial

Indications: Leukemia

Partnerships

Eli Lilly and CompanyNovo HoldingsBristol Myers SquibbAcademic institutionsHealthcare service providers

Beyond the preview

Go deeper on BioGeneration Ventures.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioGeneration Ventures.

Explore the full profile